Moneycontrol PRO
UPCOMING EVENT:Special webinar on Highlights of global investing in 2021 and what lies ahead' at 2 pm on 21st January, 2022. Register Now!
you are here: HomeNewsTrends

Centre approves Rs 350 crore to setup 16 API manufacturing plants under incentive scheme

According to the Chemicals and Fertilisers Ministry, the government will invest Rs 348.70 crore in the setting of these plants which will make the country self-reliant with respect to these bulk drugs. The commercial production of these plants is projected to commence on 1 April 2023.

April 13, 2021 / 06:49 PM IST
Lincoln Pharmaceuticals | ICRA has upgraded company's long term rating to ICRA A and short term rating to ICRA A1

Lincoln Pharmaceuticals | ICRA has upgraded company's long term rating to ICRA A and short term rating to ICRA A1

Government on April 13 approved funds to set up 16 manufacturing plants for Active Pharmaceutical Ingredients (API) in the country under the production-linked incentive scheme for active pharmaceutical ingredients.

According to the Chemicals and Fertilisers Ministry, the government will invest Rs 348.70 crore in the setting of these plants which will make the country self-reliant with respect to these bulk drugs. The commercial production of these plants is projected to commence on 1 April 2023.

The government's move comes in the wake of states reporting a shortage of vaccines for COVID-19, at a time when the country is witnessing a resurgence in coronavirus cases. On March 13th the country reported 1,61,736 new cases in the past 24 hours.

The government has given the approval to set up manufacturing plants for active pharmaceutical ingredients including Valsartan, Losartan, Levofloxacin, Sulfadiazine, Ciprofloxacin, Ofloxacin, Telmisartan, Diclofenac Sodium, Levetiracetam, Carbidopa, and Levodopa.

Last month, the government had approved a total of 33 applications with a committed investment of Rs 5,082.65 crore under the Production Linked Incentive scheme for Active Pharmaceutical Ingredients.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Under the production-linked incentive scheme for active pharmaceutical ingredients, the government has received a total of 215 applications have been received for 36 products spread across the four target segments.

Nineteen applications with a committed investment of Rs 4,623.01 crore have already been approved under target segments I, II, and III, the government said in a press release.

Besides, 174 applications were received for 23 products under target segment IV -- other chemical synthesis-based KSMs or drug intermediates or APIs.

79 of them received for 11 eligible products were considered as per the decided evaluation and selection criteria.

Applications of 14 companies that have committed minimum/more than the minimum proposed annual production capacities and fulfill the prescribed criteria have been approved, the ministry said.

The Indian pharmaceutical industry is the 3rd largest in the world by volume. It has a high market presence in several advanced economies such as the US and EU. The industry is well known for its production of affordable medicines, particularly in the generics space. However the country is significantly dependent on the import of basic raw materials, viz., Bulk Drugs that are used to produce medicines. In some specific bulk drugs, the import dependence is 80 to 100 per cent.
first published: Apr 13, 2021 06:49 pm

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark